Phenotypes and endotypes of uncontrolled severe asthma: New Treatments

Journal of Investigational Allergology and Clinical Immunology

Volumn 23, Issue 2, 2013, Pages 76-88

  Campo, P ^a   Rodriguez F ^b   Sanchez Garcia S ^c   Barranco, P ^d   Quirce, S ^d   Perez Frances C ^e   Gomez Torrijos E ^f   Cardenas R ^f   Olaguibel, J M ^g   Delgado, J ^h  

^a Hospital General de Málaga   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^g Universidad Pública de Navarra   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Biomarkers; Endotype; Phenotype; Severe asthma; Treatment

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; 5 ALLYL 1,2 DIHYDRO 10 METHOXY 2,2,4 TRIMETHYL 5H 1 BENZOPYRANO[3,4 F]QUINOLINE; ALTRAKINCEPT; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROQUINE; CILOMILAST; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; FLUTICASONE; FORMOTEROL; GOLIMUMAB; IMMUNOGLOBULIN E; INDACATEROL; INFLIXIMAB; MACROLIDE; MEPOLIZUMAB; METHOTREXATE; PIMECROLIMUS; PITRAKINRA; ROFLUMILAST; SALMETEROL; TACROLIMUS; TIOTROPIUM BROMIDE; TPI ASM 8; TSI ASM 8; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIRWAY OBSTRUCTION; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; ATOPIC DERMATITIS; BRONCHIAL THERMOPLASTY; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIARRHEA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOMODULATION; KIDNEY GRAFT REJECTION; LIVER FUNCTION TEST; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; NEUTROPHILIA; NONHUMAN; PHENOTYPE; PHYSICAL MEDICINE; REVIEW; RISK BENEFIT ANALYSIS; SEVERE PERSISTENT ASTHMA; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL MARKERS; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 84875469363     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP, Dweik RA, Fitzpatrick AM, Gaston B, Hew M, Hussain I, Jarjour NN, Israel E, Levy BD, Murphy JR, Peters SP, Teague WG, Meyers DA, Busse WW, Wenzel SE. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405-13.
2. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, Brightling CE, Busse WW, Castro M, Dahlen B, Dahlen SE, Fabbri LM, Holgate ST, Humbert M, Gaga M, Joos GF, Levy B, Rabe KF, Sterk PJ, Wilson SJ, Vachier I. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol. 2007;119:1337-48.
3. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exper Allergy. 2012;42:650-8.
4. Gaga M, Zervas E, Gibson PG. Allergic and non-allergic factors in severe asthma. Eur Respir Mon. 2011;51:107-19.
5. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66:910-7.
6. ten Brinke A, Sterk PJ, Masclee AA, Spinhoven P, Schmidt JT, Zwinderman AH, Rabe KF, Bel EH. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26:812-8.
7. Miller MK, Lee JH, Miller DP, Wenzel SE; TENOR Study Group. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007;101:481-9.
8. Barranco P, Pérez-Francés C, Quirce S, Gómez-Torrijos E, Cárdenas R, Sánchez-García S, Rodríguez-Rodríguez F, Campo P, Olaguibel JM, Delgado J (Severe Asthma working group of SEAIC). Consensus document on the diagnosis of severe uncontrolled asthma. J Investig Allergol Clin Immunol. 2012;22:460-75.
9. Wenzel SE. Asthma exacerbations in relation to severe asthma. Eur Respir Mon. 2011;51:120-9.
10. Romagnoli M, Caramori G, Braccioni F, Ravenna F, Barreiro E, Siafakas NM, Vignola AM, Chanez P, Fabbri LM, Papi A; and the ENFUMOSA Study Group. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy. 2007;37:552-7.
11. Zambrano JC, Carper HT, Rakes GP, Patrie J, Murphy DD, Platts-Mills TA, Hayden FG, Gwaltney JM Jr, Hatley TK, Owens AM, Heymann PW. Experimental rhinovirus infection challenges in adults with mild asthma: response to infection in relation to IgE. J Allergy Clin Immunol. 2003;111:1008-16.
12. Sandford AJ, Chagani T, Zhu S, Weir TD, Bai TR, Spinelli JJ, Fitzgerald JM, Behbehani NA, Tan WC, Paré PD. Polymorphisms in the IL4, IL4RA and FCERIB genes and asthma severity. J Allergy Clin Immunol. 2000;106:135-40.
13. Calhoun WJ, Swenson CA, Dick EC, Schwartz LB, Lemanske RF Jr, Busse WW. Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects. Am Rev Respir Dis. 1991;144:1267-73.
14. Innes AL, Carrington SD, Thornton DJ, Kirkham S, Rousseau K, Dougherty RH, Raymond WW, Caughey GH, Muller SJ, Fahy JV. Ex vivo sputum analysis reveals impairment of proteasedependent mucus degradation by plasma proteins in acute asthma. Am J Respir Crit Care Med. 2009;180:203-10.
15. Bel EH, ten Brinke A, Sorkness RL. Fixed airway obstruction in severe asthma. Eur Respir Mon. 2011;51:147-59.
16. Ulrik CS, Backer V. Nonreversible airflow obstruction in lifelong nonsmokers with moderate to severe asthma. Eur Respir. 1999;14:892-6.
17. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007;132:1882e9.
18. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med. 2004;10:44e50.
19. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, Pandit S, McKenny J, Braunschweiger K, Walsh A, Liu Z, Hayward B, Folz C, Manning SP, Bawa A, Saracino L, Thackston M, Benchekroun Y, Capparell N, Wang M, Adair R, Feng Y, Dubois J, FitzGerald MG, Huang H, Gibson R, Allen KM, Pedan A, Danzig MR, Umland SP, Egan RW, Cuss FM, Rorke S, Clough JB, Holloway JW, Holgate ST, Keith TP. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002;418:426-30.
20. Le Moual N, Siroux V, Pin I, Kauffmann F, Kennedy SM; Epidemiological Study on the Genetics and Environment of Asthma. Asthma severity and exposure to occupational asthmogens. Am J Respir Crit Care Med. 2005;172:440-5.
21. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172:149-60.
22. Chung KF, Gibeon D, Dirham A, Marwick J, Bhavsar P, Adcock I. Corticosteroids: use and insensitivity in severe asthma. Eur Resp Mon. 2011;51;236-52.
23. Sher ER, Leung DY, Suru W, Kam JC, Zieg G, Kamada AK, Szefler SJ. Steroid-resistant asthma: cellular mechanism contributing to inadequate response to glucocorticoid therapy. J Clin Invest. 1994;93:33-9.
24. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol. 1993;151:3460-6.
25. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol. 2004;113:1100-8.
26. Leung DY, Hamid QA, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, Klemm DJ. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor ß. J Exp Med. 1997;186:1567-74.
27. Hamid QA, Wenzel SE, Hauk PJ, Hauk PJ, Tsicopoulos A, Wallaert B, Lafitte JJ, Chrousos GP, Szefler SJ, Leung DY. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Resp Crit Care Med. 1999;159:1600-4.
28. Ito K, Barnes PJ, Adcok IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000;20:6891-903.
29. Chung KF, Marwick J. Molecular mechanisms of oxidative stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease. Ann NY Acad Sci. 2010;1203:85-91.
30. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168:1308-11.
31. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4 T cells. J Clin Invest. 2004;113:619-27.
32. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and corticoid response in asthma. Am J Respir Crit Care Med. 2008;178:682-7.
33. Marwick JA, Caramori G, Casolari P, Mazzoni F, Kirkham PA, Adcock IM, Chung KF, Papi A. A role of phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2010;125:1146-53.
34. Bhavsar PK, Levy BD, Hew MJ, Pfeffer MA, Kazani S, Israel E, Chung KF. Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir Res. 2010;11:71.
35. Hakonarson H, Bjornsdottir US, Halapi E, Bradfield J, Zink F, Mouy M, Helgadottir H, Gudmundsdottir AS, Andrason H, Adalsteinsdottir AE, Kristjansson K, Birkisson I, Arnason T, Andresdottir M, Gislason D, Gislason T, Gulcher JR, Stefansson K. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA. 2005;102:14789-94.
36. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med. 2004;170:601-5.
37. Teng Y, Sun P, Zhang J, Yu R, Bai J, Yao X, Huang M, Adcock IM, Barnes PJ. Hydrogen peroxide in exhaled breath condensate in patients with asthma: a promising biomarker? Chest. 2011;140:108-16.
38. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368:804e13.
39. Gibson PG, Wang F, He XY, Brightling CE. Noninvasive assessment of inflammation in severe asthma. Eur Resp Mon. 2011;51:208-17.
40. Simpson JL, Word LG, Gibson PG. Inflammatory mediators in exhaled breath, induced sputum and saliva. Clin Exp Allergy. 2005;35:1180-5.
41. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, Zamel N. Exhaled nitric oxide in pulmonary diseases: a comprehensive review Chest. 2010;138:682-92
42. Montuschi P, Santonico M, Mondino C, Pennazza G, Mantini G, Martinelli E, Capuano R, Ciabattoni G, Paolesse R, Di Natale C, Barnes PJ, D'Amico A. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide and lung function testing in asthma. Chest. 2010;137:790-6.
43. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715-21.
44. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-84.
45. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113:101-8.
46. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003;22(3):470-7.
47. Gagliardo R, Chanez P, Vignola AM, Bousquet J, Vachier I, Godard P, Bonsignore G, Demoly P, Mathieu M. Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med. 2000;162:7-13.
48. Fitzpatrick AM, Teague WG. Severe Asthma in Children: Insights from the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Pediatr Allergy Immunol Pulmonol. 2010;23(2):131-8.
49. Bush A, Fleming L. Phenotypes of refractory/severe asthma. Paediatr Respir Rev. 2011;12(3):177-81. Epub 2011 Feb 22.
50. He XY, Simpson JL, Wang F. Inflammatory phenotypes in stable and acute childhood asthma. Paediatr Respir Rev. 2011;12(3):165-9.
51. Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG; National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. J Allergy Clin Immunol. 2006;118(6):1218-25.
52. Marguet C, Bocquel N, Benichou J, Basuyau JP, Hellot MF, Couderc L, Mallet E, Macé B. Neutrophil but not eosinophil inflammation is related to the severity of a first acute epidemic bronchiolitis in young infants. Pediatr Allergy Immunol. 2008;19(2):157-65.
53. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003;349(15):1414-22.
54. de Blic J, Tillie-Leblond I, Tonnel AB, Jaubert F, Scheinmann P, Gosset P. Difficult asthma in children: an analysis of airway inflammation. J Allergy Clin Immunol. 2004;113(1):94-100.
55. Stern DA, Morgan WJ, Halonen M, Wright AL, Martinez FD. Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in arly adulthood: a longitudinal birth-cohort study. Lancet. 2008;372(9643):1058-64.
56. Liu AH, Zeiger RS, Sorkness CA, Ostrom NK, Chipps BE, Rosa K, Watson ME, Kaplan MS, Meurer JR, Mahr TA, Blaiss MS, Piault-Louis E, McDonald J. The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. J Allergy Clin Immunol. 2010;126(2):267-73, 273. e1. Epub 2010 Jul 10.
57. Bossley CJ, Saglani S, Kavanagh C, Payne DN, Wilson N, Tsartsali L, Rosenthal M, Balfour-Lynn IM, Nicholson AG, Bush A. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. Eur Respir J. 2009;34(5):1052-9.
58. Coren ME, Rosenthal M, Bush A. The use of cyclosporine in corticosteroid dependent asthma. Arch Dis Child. 1997;77(6):522-3.
59. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol. 1996;98(2):317-24.
60. Solé D, Costa-Carvalho BT, Soares FJ, Rullo VV, Naspitz CK. Methotrexate in the treatment of corticodependent asthmatic children. J Investig Allergol Clin Immunol. 1996;6(2):126-30.
61. Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, Simons FE, Weiss ST, Wenzel SE, Borish L, Bleecker ER; TENOR Study Group. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2009;124(5):895-902.
62. Ayres JG, Miles JF, Barnes PJ. Brittle asthma. Thorax. 1998;53(4):315-21.
63. Vicencio AG, Muzumdar H, Tsirilakis K, Kessel A, Nandalike K, Goldman DL. Severe asthma with fungal sensitization in a child: response to itraconazole therapy. Pediatrics. 2010;125(5):e1255-8.
64. Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax. 2012;67(8):675-81. Epub 2012 Feb 29.
65. Gibson PG, Simpson JL, Hankin R, Powell H, Henry RL. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax. 2003;58(2):116-21.
66. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-84.
67. Fitzpatrick AM, Baena-Cagnani CE, Bacharier LB. Severe asthma in childhood: recent advances in phenotyping and pathogenesis. Curr Opin Allergy Clin Immunol. 2012;12(2):193-201.
68. Siroux V, Garcia-Aymerich J. The investigation of asthma phenotypes. Curr Opin Allergy Clin Immunol. 2011;11:393-9.
69. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315e23.
70. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, Wenzel SE, Aujla S, Castro M, Bacharier LB, Gaston BM, Bleecker ER, Moore WC. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011;127(2):382-9, e1-13.
71. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol. 1999;103(2 Pt 1):232-7.
72. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF, Jr, Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-60.
73. Quirce S, Bobolea I, Barranco P. Emerging drugs for asthma. Expert Opin Emerg Drugs. 2012;17:219-37.
74. Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med. 2008;102:1499-1510.
75. Comet R, Domingo C, Larrosa M, Morón A, Rué M, Amengual MJ, Marín A. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A doubleblind, randomized, placebo controlled study. Respir Med. 2006;100:411-9.
76. Trigg CJ, Davies RJ. Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study. Resp Med.1993;87:211-6.
77. Domingo C, Moreno A, Amengual MJ, Comet R, Lujan M. Twelve years' experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin. 2009;25:367-74.
78. Aaron SD, Dales RE, Pham B. Management of steroiddependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Resp Med. 1998;92:1059-65.
79. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000(2):CD000391.
80. Marin MG. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Chest. 1997;112:29-33.
81. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001:CD002993.
82. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001(2):CD002985.
83. Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev. 2004(1):CD003270.
84. Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Chloroquine as a steroid sparing agent for asthma. Cochrane Database Syst Rev. 2003(4):CD003275.
85. Kozyrskyj AL, Dahl ME, Ungar WJ, Becker AB, Law BJ. Antibiotic treatment of wheezing in children with asthma: what is the practice? Pediatrics. 2006;117:1104-10.
86. Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis? Am J Respir Crit Care Med. 2005;172:1078-9.
87. Richedl L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma: Cochrane Database Syst Rev. 2005(3):CD002997.
88. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148.
89. Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE, Marschke K, Rosen J, Vajda E, Zhi L, Negro-Vilar A. Antiinflammatory glucocorticoid ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA. 2007;104:19244-9.
90. LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, Owen R, Higgins M. Indacaterol provides sustained 24 h bronchodilatation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy. 2008;63:103-11.
91. Cazzola M, Calzetta L, Matera MG. Beta2 adrenoceptor agonist. Current and future direction. Br J Pharmacol. 2011;163:4-17.
92. GINA Global Initiative for Asthma. Global strategy for asthma management and prevention NHBLI/WHO Workshop Report. 2007. Available from htpp://www.ginasthma.com.
93. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2008;63(Suppl 4):1-121.
94. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Craig T, Denlinger L, Engle LL, DiMango EA, Fahy JV, Israel E, Jarjour N, Kazani SD, Kraft M, Lazarus SC, Lemanske RF Jr, Lugogo N, Martin RJ, Meyers DA, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Wasserman SI, Walter MJ, Wechsler ME, Chinchilli VM, Bleecker ER; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Eng J Med. 2010;363:1715-26.
95. Kerstjens HA, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, Engel M, van Noord JA. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128:308-14.
96. Bateman ED, Izquierdo JL, Harnest U, Hofbauer P, Magyar P, Schmid-Wirlitsch C, Leichtl S, Bredenbröker D. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;96:679-86.
97. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006(2):CD003559.
98. Stirling RG, van Rensen EL, Barnes PJ, Chung KF. Interleukin-5 induces CD34+ eosinophil progenitor mobilisation and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001;164:1403-9.
99. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-84.
100. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM; IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001;107:963-70.
101. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect on an interleukin-4 variant on the late asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370:1422-31.
102. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT. The effects of monoclonal antibody directed against tumor necrosis factor-_ in asthma. Am J Respir Crit Care Med. 2006;174:753-62.
103. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID. Evidence of role of tumor necrosis factor-_ in refractory asthma. N Engl J Med. 2006;354:697-708.
104. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators. A randomized double-blind placebo controlled study of tumor necrosis factor-_ blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549-58.
105. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, Vexler V, Shames RS; Daclizumab Asthma Study Group. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178:1002-8.
106. Gauvreau GM, Pageau R, Séguin R, Carballo D, Gauthier J, D'Anjou H, Campbell H, Watson R, Mistry M, Parry-Billings M, Killian K, Renzi PM. Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy. 2011;66:1242-8.
107. Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med. 2006;173:965-9.
108. Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med. 2012;185(7):709-14.
109. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2):116-24.
110. Boulet LP, Laviolette M. Is there a role for bronchial thermoplasty in the treatment of asthma? Can Respir J. 2012;19(3):191-2